Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on capital for shareholders in 2024.

The reason? Investors have flocked to the biotech stock in response to its experimental weight loss therapy, VK2735. This is a peptide GLP-1/GIP dual agonist being trialed in both a subcutaneously injected and an oral dosage form.

Image source: Getty Images.

Continue reading

Source Fool.com